Stuart Therapeutics regularly attends industry innovation and partnering conferences in both the United States and Europe. Please don’t hesitate to look us up there.


For partnering inquiries, or other questions, please contact us below:

Stuart Therapeutics is committed to rapidly developing the power of the PolyCol platform technology to deliver transformative, enhanced therapies to the widest range of applicable diseases as quickly as possible.

The PolyCol platform spans a wide range of disease areas. While we may expand into other disease areas in the future, our current focus is on ophthalmic conditions, which enables a cost-efficient discovery and development strategy.

Eric Schlumpf
President and CEO
Cell: 206.228.2781

Shawn DeLorey
SVP, Program Management and Corporate Development
Cell: 617.513.2701